<p>Entera Bio（納斯達克代碼：ENTX - 獲取免費報告）於週五公佈了季度財報。該公司報告每股收益為（$0.06），超出分析師一致預期的（$0.08）$0.02，Zacks 報道。</p>
<h2>Entera Bio 股價表現</h2>
<p>週五中午交易時，納斯達克 ENTX 的股價下跌 $0.05，達到 $1.75。該公司的股票交易量為 55,218 股，而其平均交易量為 120,233 股。該公司的市值為 6262 萬美元，市盈率為 -6.73，貝塔係數為 1.62。該公司的 50 日簡單移動平均線為 $2.15，200 日簡單移動平均線為 $2.02。Entera Bio 的一年低點為 $1.41，一年高點為 $3.35。</p>
<h2>分析師設定新目標價</h2>
<p>另外，HC Wainwright 在 3 月 18 日的研究報告中重申了對 Entera Bio 的 “買入” 評級，並設定了 $10.00 的目標價。</p>
<p><strong>閲讀我們關於 Entera Bio 的最新報告</strong></p>
<h2>關於 Entera Bio</h2>
<p>（獲取免費報告）</p>
<p>Entera Bio Ltd. 是一家臨牀階段公司，專注於開發和商業化口服給藥的肽和蛋白質治療藥物，以滿足未滿足的醫療需求。該公司的產品候選者包括 EB612，目前正在進行治療甲狀旁腺功能減退症的二期臨牀試驗；以及 EB613，該藥物已完成治療骨質疏鬆症的二期臨牀試驗，並正在進行治療應力性骨折的一期臨牀試驗。</p>
<h2>推薦故事</h2>
<ul>
<li>我們更看好的五隻股票比 Entera Bio 更好</li>
<li>股票中的死亡交叉是什麼？</li>
<li>為什麼 Dollar Tree 的 Family Dollar 銷售可能會引發復甦</li>
<li>即將到來的 IPO 股票鎖定期，解釋</li>
<li>摩根大通：銀行業的 “英偉達” 準備獲得更多收益？</li>
<li>專家股票交易心理學技巧</li>
<li>購買 Chewy 股票反轉？現在是時候了</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RU5UWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RU5UWA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 $1,000 在 Entera Bio 嗎？</h2>
<p>在考慮 Entera Bio 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Entera Bio 並不在名單上。</p>
<p>雖然 Entera Bio 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

ENTX

<p>Entera Bio（納斯達克代碼：ENTX）報告的季度每股收益為（$0.06），超出分析師預期的（$0.08）$0.02。該股下跌$0.05，報$1.75，市值為$6262 萬。HC Wainwright 的分析師維持 “買入” 評級，目標價為$10.00。Entera Bio 專注於開發口服給藥的肽和蛋白質治療藥物，目前有針對甲狀旁腺功能減退症和骨質疏鬆症的候選藥物在臨牀試驗中</p>

<p>Entera Bio (NASDAQ:ENTX - Get Free Report) announced its quarterly earnings results on Friday. The company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.08) by $0.02, Zacks reports.</p>
<div class="lb-trans"><p>Entera Bio（納斯達克代碼：ENTX - 獲取免費報告）於週五公佈了季度財報。該公司報告每股收益為（$0.06），超出分析師一致預期的（$0.08）$0.02，Zacks 報道。</p>
</div><h2>Entera Bio Price Performance</h2>
<div class="lb-trans"><h2>Entera Bio 股價表現</h2>
</div><p>Shares of NASDAQ ENTX traded down $0.05 during mid-day trading on Friday, hitting $1.75. The company's stock had a trading volume of 55,218 shares, compared to its average volume of 120,233. The stock has a market cap of $62.62 million, a price-to-earnings ratio of -6.73 and a beta of 1.62. The company's fifty day simple moving average is $2.15 and its 200-day simple moving average is $2.02. Entera Bio has a one year low of $1.41 and a one year high of $3.35.</p>
<div class="lb-trans"><p>週五中午交易時，納斯達克 ENTX 的股價下跌 $0.05，達到 $1.75。該公司的股票交易量為 55,218 股，而其平均交易量為 120,233 股。該公司的市值為 6262 萬美元，市盈率為 -6.73，貝塔係數為 1.62。該公司的 50 日簡單移動平均線為 $2.15，200 日簡單移動平均線為 $2.02。Entera Bio 的一年低點為 $1.41，一年高點為 $3.35。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>Separately, HC Wainwright restated a &#34;buy&#34; rating and issued a $10.00 price objective on shares of Entera Bio in a research report on Tuesday, March 18th.</p>
<div class="lb-trans"><p>另外，HC Wainwright 在 3 月 18 日的研究報告中重申了對 Entera Bio 的 “買入” 評級，並設定了 $10.00 的目標價。</p>
</div><p><strong>Read Our Latest Report on Entera Bio</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 Entera Bio 的最新報告</strong></p>
</div><h2>About Entera Bio</h2>
<div class="lb-trans"><h2>關於 Entera Bio</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.</p>
<div class="lb-trans"><p>Entera Bio Ltd. 是一家臨牀階段公司，專注於開發和商業化口服給藥的肽和蛋白質治療藥物，以滿足未滿足的醫療需求。該公司的產品候選者包括 EB612，目前正在進行治療甲狀旁腺功能減退症的二期臨牀試驗；以及 EB613，該藥物已完成治療骨質疏鬆症的二期臨牀試驗，並正在進行治療應力性骨折的一期臨牀試驗。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Entera Bio</li>
<li>What is a Death Cross in Stocks?</li>
<li>Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback</li>
<li>Upcoming IPO Stock Lockup Period, Explained</li>
<li>JPMorgan: The 'NVIDIA of Banking' Poised for More Gains?</li>
<li>Expert Stock Trading Psychology Tips</li>
<li>Buy the Chewy Stock Reversal? Here’s Why Now Is the Time</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Entera Bio 更好</li>
<li>股票中的死亡交叉是什麼？</li>
<li>為什麼 Dollar Tree 的 Family Dollar 銷售可能會引發復甦</li>
<li>即將到來的 IPO 股票鎖定期，解釋</li>
<li>摩根大通：銀行業的 “英偉達” 準備獲得更多收益？</li>
<li>專家股票交易心理學技巧</li>
<li>購買 Chewy 股票反轉？現在是時候了</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RU5UWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=ENTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Entera Bio Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 $1,000 在 Entera Bio 嗎？</h2>
</div><p>Before you consider Entera Bio, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Entera Bio 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Entera Bio wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Entera Bio 並不在名單上。</p>
</div><p>While Entera Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Entera Bio 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Entera Bio（納斯達克：ENTX）公佈了財報結果